Subject Index
Total Page：16
File Type：pdf, Size：1020Kb
Subject Index A-64662 497 classification 11-14 AA-861 511 (fig) function 111-114 acebutolol 69,70 hemodynamic effects 110-121 brand names 868 (table) in hypertensive disease 114 dosage 83 (table), 860 (table) mechanism of action 110-121 intrinsic sympathomimetic activity 82 metabolism 108-110 pharmacological profile 83 (table) pharmacodynamics 110-121 see also diuretics 83 pharmacokinetics 108-110 acetazolamide 22, 24 sUbtypes 111,241-246 chemical structure 23 (fig), 24 (table) a2- 246 duration of action 39 (table) classification at central cardiovascular fractional sodium excretion 30 (table) sites 242-244 metabolism 37 definition at peripheral sites onset of action 39 (table) 241-242 peak of action 39 (table) a-adrenoceptor agonists 113 (table) pKa 37 (table) a-adrenoceptor antagonists 15, 105-125 plasma elimination half-life 37 antihypertensive activity 114-119 protein binding 37 (table) chemistry 106-108 renal site/mechanism of action 26, 30 combination with other drugs 123 (table) contraindications 123-124 site of action 29 differential antagonism 242 teratogenesis 800,800-802 dosage 121-123 tubular fluid/plasma-sodium drug interactions 123 concentrations ratio 30 (fig) effects on: c10nidine 240-241 see also diuretics guanfacine 240-241 acetylcholine 316 a-methyldopa 240-241 acetylsalicylic acid 53 hemodynamic profile 119-120 Actinomycetales extracts/compounds side effects 124 728 therapeutic use 121-123 adenosine-3, 5-cyclic monophosphate toxicity 124 (cAMP) 73 ~-adrenoceptor antagonists 66-67, 815 adenosine triphosphate 73,268 a-adrenoceptor stimulating drugs adenyl ate cyclase 73 cerebral application 241 adimolol 134,135 (table), 196 afzelin 721 chemistry 136 (table) agonist-antagonist interaction curves 73 adolescent children of hypertensive (fig) parents 9 ahpatinins 487 adrenaline 67,75,113 (table), 243 alacepril 418-419 (table) (table), 522 (table) [14C) alacepril 444 non-selective agonist 112 aldehyde 28 489 adrenergic synapse 111 (fig) aldosterone antagonists 22,24 (table), 25 adrenergic system inhibitors 14-15,751 aldosterone, sodium pump control 28,44 a-adrenoceptor(s) 110-114,815 aldosteronism, primary 32,41,315 brainstem location 112 dopaminergic control of secretion central 239-240 569-570 a 14,117 enzyme secretion 36 902 Subject Index algae extracts/compounds 729 concentration in monkey cardiac alkylpyiidylguanidines (PI 060, PI 075) tissue 436 (fig) 646 (fig) conversion to angiotensin II 429 alkylpyridylthiourea (P950) 646 (fig) blocking 427 alprenolol 71,83 (table) PGI2/PGE2 release from kidney 516 brand names 868 (table) vascular wall 441-442 dosage 83 (table), 860 (table) angiotensin II 32,34,45,400,401-405 alseroxylon (table),431 brand names 868 (table) cardiac effects 437 dosage 866 concentration in monkey cardiac aluminium hydroxide 71 tissue 436 (fig) Amelanchier ovalis 732 faciIitatory action on sympathetic amiloride 25,813 nervous system 426 bioavailabiIity 37 (table) intrarenal actions 432 brand names 868 (table) release from isolated mesenteric arteries clinical structure 23 (fig), 24 (table) 426 dosage 863 (table) vascular wall generation 441,446-447 duration of action 38, 39 (table) unrelated effects 447-449 fractional sodium excretion 30 (table) vasoconstrictor effect 427 -428 intestinal absorption 36 angiotensin III 436 (fig) onset of action 39 (table) angiotensin converting enzyme 381 (fig) oral dose 40 (table) angiotensin converting enzyme inhibitors peak of action 39 (table) 41,43,483,750-751 plasma elimination half-life 37 (table) fetotoxicity 799-800 primary aldosteronism treatment 41 renal changes 789-794 protein binding 36,37 (table) blood urea levels 791-792 renal site/mechanism of action 26 juxtaglomerular apparatus 792-793 side effects 52 renal tubule integrity 790-791 target site 28 renal vasculature 794 tubular fluid/plasma-sodium angiotensinogen mRNA 436 concentration ratios 30 (fig) see also tenin inhibitors see alsQ diuretics aortic chemoreceptors 78 21-amino acid peptide see endothelin apomorphine 562 (fig), 576-577 amino alcohol 40 489 cardiovascular action 579 (table) 20-amino-3-(3-hydroxy-5-pregnene-(3- spinal site . 577 D-glucoside 720 aprotinin 410 (table), 447 amosulalol 134,135 (table), 178-181 arachidonic acid 35, 507, 508 chemistry 135 (table), 178 antihypertensive drugs effect on hemodynamics 179-180 metabolism 523 metabolism 180 metabolism in kidney 513 mode of action 178-179 metabolites 507-508 pharmacodynamics 139 (table), products, blood pressure control 178-179 512-522 pharmacokinetics 180 renal circulation effects 513-514 side effects 181 Arachis hypogea 732 therapeutic use 180-181 Arctium lappa Iignans 724-725 toxicology 180 arloxyisopropanolamines 134 amrinone, myocardial necrosis arotinolol 134,135 (table), 139 (table), associated 795 174-178 anatomical-therapeutic-chemical brand names 868 (table) classification system (ATe system) chemistry 135 (table), 174 820 dosage 860 (table) Anemonia sulcata peptides 730 elimination half-life 178 angioneurotic edema 457-458 hemodynamics 176-177 angiotensin, vascular, locally metabolism pathways 510 (fig) generated 441 mode of action 175-176 angiotensin I 400,401-405 (table), pharmacodynamics 175-176 427-429 pharmacokinetics 178 Subject Index 903 therapeutic use 178 renal site/method of action 26 arterial media, cross-sectional area benzothiadiazine-related heterocyclics 25 448 (table) benzthiazide 25 arylethanolamines 133-134 brand names 869 (table) aryloxyacetic acids 22,24 (table) dosage 863 (table) aryltetranaphthalenes 725 benzylhydrochlorthiazide aspartyl proteases 485 brand names 869 (table) aspirin 511 (fig) dosage 863 (table) asthmatics· 79 D-2-benxylsuccinic acid 383 astragalin 721 betaxolol atenolol 69,70 brand name 869 (table) fi-blocking action 74 (table) dosage 860 (table) brand names 868 (table) bethanidine 228 (fig), 294 dosage 83 (table), 860 (table) brand names 869 (table) elimination half-life 72 dosage 865 (table) excretion 71 bevantolol 134,136 (table), 167-174 intestinal absorption 70-71 adrenoceptor blocking activity 139 log partition coefficient 70 (table),168-169 pharmacological profile 83 (table) brand names 869 (table) see also ~-blockers chemistry 136 (table), 167-168 atrial natriuretic factor 570 dosage 860 (table) atrial natriuretic peptide 6712-624 hemodynamics 169-171 chemistry 612-614 metabolism 172 effects: mode of action 168-169 biological 615-616 pharmacodynamics 168-169 blood pressure 617-619 pharmacology 168 hypertension 621-624 pharmacokinetics 171-172 renin secretion 616-617 side effects 174 mechanism of action 620-621 therapeutic use 172-173 receptor 620-621 toxicology 171 release regulation 614-615 B-HT920 113 (table), 230, 243 (table) synthesis regulation 614-615 B-HT933 (azepexole) 113 (table), 230, autoregulatory hypothesis 8-9 243 (table) avian pancreatic polypeptide 606 biofeedback-based behavioral therapy azamethonium 844 brand names 868 (table) bisoprolol dosage 865 (table) brand names 869 (table) azepexole (B-HT933) 113 (table), 230, dosage 860 (table) 243 (table) ~-blockers 66-93, 132-200,748-749 azosemide 25 cardioselectivity 70 dosage 863 (table) chemistry 68-70 brand names 868 (table) combinations 90 teratogenesis 802-803 contraindications 15,91 azotemia, prerenal 51 distribution 71 enantiomers 137 B24n6 196, 198 (table) excretion 71-72 baroreceptorreftex 78,240,314 hepatic metabolism 71 Bartter's syndrome 516 history 66-68 BAY K 8644 307, 309 interactions, pharmacokinetic/ behavioral intervention 778 (fig) pharmacodynamic 6-7 benazepril 386 intrinsic stimulant activity 82-85 bendroftumethiazide (bendroftuazide) 25 intrinsic sympathomimetic activity brand names 868-869 (table) 68-70 dosage 863 (table) isomerism 70 benign essential tremor 79 mechanism of action 72-88 4-(2-benzo(b )furanyl)coumarins 723 baroreftex 78 benzothiadiazine(s) 24 blood pressure lowering 85-88 benzothiadiazine derivatives 22,24-25 catecholamines 77 904 Subject Index cellular processes 72-74 peak of action 39 (table) central nervous effects 79 pKa 37 (table) cheDloreftexes 78 plasDla eliDlination half-life 37 (table) glucose DletabolisDl 80 protein binding 37 (table) heart 75 relative natriuretic potency 31 (table) intra-orbital pressure reduction 85 renal heDlodynaDlics 31 intrinsic sYDlpathoDliDletic activity renal site/DlechanisDl of action, 26,30 81-85 (table) lipid DletabolisDl 80-81 tubular ftuid/plasDla-sodiuDl nerve activity 77-78 concentrations 30 (fig) peripheral autonoDlic nerves 72 see also diuretics peripheral blood vessels 75-76 bunazosin plasDla renin activity 77 brand naDles 869 (table) platelet agregation inhibition 85 dosage 866 (table) renal effect 76 bunitrolol respiratory effects 79-80 brand naDles 870 (table) seruDl potassiuDl 81 dosage 860 (table) tear reduction 85 bupranolol throDlboxane production reduction brand naDles 870 (table) 85 dosage 860 (table) thyroid 81 butanolides 724-725 treDlor 79 buthiazide (butizide) overdosage 92 brand naDles 870 (table) pharDlacokinetics 70-72 dosage 863 (table) side effects 91-92 BW 855C 511 (fig) stereospecificity 134-137 BW A575C 134,136 (table), 194-195 therapeutic use 88-89 cheDlistry 136 (table), 194 toxicity 92 pharDlacology 195 blood pressure, persistence of norDlal, after withdrawal of drug therapy cadralazine 755-761 brand naDles 870 (table) blood vessels dosage 866 (table) eicosanoids generation 519-520 calcitonin, Dlessenger RNA encoding 601 endothelial cell role in hypertension calcitonin gene related peptide 601-605 520 aDlino acid sequence 602 (fig) bODletolol 196,198 (table) anatoDlical distribution 601-603 bopindolol